Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.40 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19903206 | 0.87 | GRM2 (0.41) | SRCCHEK1MAPTMEN1KMT2A | |
| SCHEMBL15498483 | 0.81 | SRC (0.49) | SRCCHEK1MAPK10FYNMAPT | |
| SCHEMBL159594 | 0.79 | NPC1 (0.58) | SRCKDRACVR1PRKAB1 | |
| SCHEMBL19291566 | 0.78 | SRC (0.49) | SRCCHEK1MAPK10FYNMAPT | |
| SCHEMBL29039484 | 0.76 | CHRNB2 (0.41) | MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15521146 | 0.76 | SRC (0.58) | SRCFYNJAK2BMPR1BBMPR1A | |
| SCHEMBL12496637 | 0.74 | MEN1 (0.50) | MAPTMEN1KMT2AJAK2KDM4E | |
| SCHEMBL15498493 | 0.73 | MAPK10 (0.47) | SRCCHEK1MAPK10FYNMAPT | |
| SCHEMBL15498479 | 0.73 | SRC (0.58) | SRCFYNMAPTBMPR1BBMPR1A | |
| SCHEMBL19291967 | 0.71 | SRC (0.67) | SRCMAPK10FYNMAPTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167060-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | ATHENEX, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167060-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | ATHENEX, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20210214305-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | ATHENEX, INC. | 2021-07-15 | — | — | US | disclosed |
| US-20190263755-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC | 2019-08-29 | — | — | US | disclosed |
| US-20180170875-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | OAKTREE FUND ADMINISTRATION, LLC | 2018-06-21 | — | — | US | disclosed |
| US-20180170875-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | OAKTREE FUND ADMINISTRATION, LLC | 2018-06-21 | — | — | US | disclosed |
| US-9926273-B2 | Composition and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9926273-B2 | Composition and methods for modulating a kinase cascade | ATHENEX, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| EP-2890680-B1 | N-(3-FLUOROBENZYL)-2-(5-(4-MORPHOLINOPHENYL)PYRIDIN-2-YL) ACETAMIDE AS PROTEIN TYROSINE KINASE MODULATORS | ATHENEX INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20140066445-A1 | Composition and Methods for Modulating a Kinase Cascade | OAKTREE FUND ADMINISTRATION, LLC | 2014-03-06 | — | — | US | disclosed |
| US-20140066445-A1 | Composition and Methods for Modulating a Kinase Cascade | OAKTREE FUND ADMINISTRATION, LLC | 2014-03-06 | — | — | US | disclosed |
| WO-2014036426-A1 | N-(3-FLUOROBENZYL)-2-(5-(4-MORPHOLINOPHENYL)PYRIDIN-2-YL) ACETAMIDE AS PROTEIN|TYROSINE KINASE MODULATORS | KINEX PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066445-A1 | Composition and Methods for Modulating a Kinase Cascade | MAP3K1, MAP3K6, MAP3K11 | SRC 96/4885CHEK1 166/4885MAPK10 46/4885 |
| US-20210214305-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K1, MAP3K6, MAP3K11 | SRC 96/4885CHEK1 166/4885MAPK10 46/4885 |
| US-20180170875-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K1, MAP3K6, MAP3K11 | SRC 96/4885CHEK1 166/4885MAPK10 46/4885 |
| US-20230167060-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K1, MAP3K6, MAP3K11 | SRC 96/4885CHEK1 166/4885MAPK10 46/4885 |
| US-20190263755-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | MAP3K1, MAP3K11, MAP3K6 | SRC 110/4885CHEK1 153/4885MAPK10 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.